Universitätsklinikum Würzburg

Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network (2021) Gay F, Guenther A, Offidani M, Engelhardt M, Salvini M, Montefusco V, Patriarca F, et al. Journal article Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia (2021) Stasik S, Eckardt JN, Kramer M, Roellig C, Kraemer A, Scholl S, Hochhaus A, et al. Journal article Plasma Metabolome Profiling for the Diagnosis of Catecholamine Producing Tumors (2021) März J, Kurlbaum M, Roche-Lancaster O, Deutschbein T, Peitzsch M, Prehn C, Weismann D, et al. Journal article Reliable and Interpretable Mortality Prediction With Strong Foresight in COVID-19 Patients: An International Study From China and Germany (2021) Bai T, Zhu X, Zhou X, Grathwohl D, Yang P, Zha Y, Jin Y, et al. Journal article Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival (2021) Julamanee J, Terakura S, Umemura K, Adachi Y, Miyao K, Okuno S, Takagi E, et al. Journal article CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma (2021) Prommersberger S, Reiser M, Beckmann J, Danhof S, Amberger M, Quade-Lyssy P, Einsele H, et al. Journal article Chronic occupational mold exposure drives expansion of aspergillus-reactive type 1 and type 2 t-helper cell responses (2021) Lauruschkat CD, Etter S, Schnack E, Ebel F, Schaeuble S, Page L, Rumens D, et al. Journal article Value of PET imaging for radiation therapy (2021) Lapa C, Nestle U, Albert NL, Baues C, Beer A, Buck A, Budach V, et al. Journal article, Review article Health-related quality of life (HRQoL) in CML-patients at diagnosis compared to general population (2021) Lorch M, Pfirrmann M, Fabisch C, Oberle L, Kohn D, Kohlbrenner K, Bruemmendorf TH, et al. Conference contribution ELDORANDO - Pembrolizumab compared with methotrexate in elderly, frail or cisplatin-ineligible patients with relapsed or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) (ELDORANDO-AIO-KHT-0115) (2021) Klinghammer K, Graeven U, Ivanyi P, Dietz A, Hahn D, Hackenberg S, Kasper S, et al. Conference contribution